EUCTR2012-000393-35-IT
Active, not recruiting
Not Applicable
a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 negative metastatic breast cancer (MBC) - protocol GOIM 21002
GOIM GRUPPO ONCOLOGICO MERIDIONALE0 sitesMarch 30, 2012
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- GOIM GRUPPO ONCOLOGICO MERIDIONALE
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. documented diagnosis of Her\-2 neg o triple neg metastatic breast cancer, 2\. age \> o \= 18 years, 3\. no prior chemiotherapy for metastatic disease, 4\. previous hormonal therapy as adjuvant or as I line treatment is allowed, 5\. previous therapy with taxanes is allowed as adjuvant or neoadjuvant treatment if completed from at least 6 months, 6\. previous treatment with anthracyclines is not mandatory, 7\. PS 0\-1, 8\. consens informed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 94
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 94
Exclusion Criteria
- •1\. documented brain metastases, 2\. sensory neuropathy more than grade 1, 3\. positive pregnancy test
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcomaEUCTR2016-002464-14-ESGrupo Español de Investigación en Sarcomas (GEIS)61
Recruiting
Phase 2
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
Completed
Phase 2
Randomized phase II study of nab-Paclitaxel (nab-PTX) plus Carboplatin(CBDCA) followed by maintenance nab-PTX or TS-1 plus CBDCA followed by maintenance TS-1 as first-line treatment in patients with stage IIIB/IV squamous cell carcinoma of the lung.squamous cell carcinoma of the lungJPRN-UMIN000012903Internationanl University of Health and Welfare, Respiratory Disease center58
Completed
Phase 2
Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.urothelial cancerJPRN-UMIN000015260Department of Urology, Saitama Medical Center, Saitama Medical University5